On June 30 - July 1, 2016, the 2nd Paris NASH Symposium French-US Meetings 2016 Edition was held in Paris, France. The symposium was organized by Arun Sanyal of the Virginia Commonwealth University School of Medicine, and Lawrence Serfaty of the Hopital Saint-Antoine, APHP, Inserm, Universite Pierre & Marie Curie.

This event was sponsored by the AFEF (Société Française d'Hépatologie) and Francaise and the French Society of Diabetes.

Click here to download the scientific program.

Presentations:

Session 1: Quantification of burden of disease
Chairs: Victor de Ledinghen (F) & Mary Rinella (US)

Modeling the epidemic of NAFLD and burden on healthcare system
Homi Razavi (US)

Variability of disease state transitions based on clinical phenotype and country of origin
Lawrence Serfaty (F)

The buren of NASH in pathology: how to recognize and how to score
Pierre Bedossa

Session 2: NAFLD and non-hepatic outcomes
Chairs: Saul Karpen (US) & Stanislas Pol (F)

NAFLD and cardiovascular disease: what is the connection?
Mary Rinella (US)

NAFLD and cancer prediction: mechanistic and clinical implications
Yujin Hoshida (US)

Reproductive health in NAFLD
Sophie Christin-Maitre (F)

Lifestyle and cancer
Jean-Francois Dufour (SWI)

Session 3: Best practices in managing NAFLD outside of hepatologists office
Chairs: Helene Hanaire (F) & Arun Sanyal (US)

Diabetes and NAFLD - the hepatologists perspective
Vlad Ratziu (F)

Does diabetes control and the means for achieving control affect various phenotypes of NAFLD
Kenneth Cusi (US)

Session 4: Emerging toolkit for NAFLD
Chairs: Jerome Boursier (F) & Jeffrey Schwimmer (US)

How Can MRI Help the Clinician?
Claude Sirlin (US)

In vitro liver models and their applications for NASH
Ajit Dash (US)

Immune activators of disease progression-diagnostic and therapeutic implications
Gyongyi Szabo (US)

Session 5: Bile acids and NAFLD
Chairs: Phillip Hylemon (US) & Raoul Poupon (F)

Separating the metabolic benefits from lipoprotein abnormalities associated with FXR agonists-gut vs liver effect
Saul Karpen (US)

Non-FXR mediated benefits of bile acids on NAFLD
Huiping Zhou (US)

Session 6: The microbiome in metabolic syndrome of NAFLD
Chairs: Harry Sokol (F) & Gyongyi Szabo (US)

The microbiome in liver disease - moving from description to mechanisms
Patrick Gillevet (US)

The bile acid biome and its relevance for NAFLD and oncogenesis
Phillip Hylemon (US)

Session 7: Regulatory issues in NAFLD
Moderator: Patrick Marcellin (F)

Special Lecture: Update from the Liver Forum and the IOM initiative
Veronica Miller (US)